A new round of medical insurance adjustment, domestic innovative drugs mess up, foreign enterprises "dividend" change?

Read: How will the health care negotiations go in 2020? What will happen to foreign drug companies that have been benefiting from health insurance? Shortly after the third batch of national collections came to an end, the State Health Insurance Administration officially released the Work Programme for the Adjustment of the National Health Insurance Drug Catalog 2020 and the Guidelines for the Adjustment and Declaration of the National Health Insurance Drug Catalog for 2020, and the declaration of the adjustment of the National Health Insurance Drug Catalog in 2020 has begun.
the 2020 health care negotiations go? What will happen to foreign drug companies that have been benefiting from health insurance? Every newly listed drug from a foreign company is actively entering the national health insurance directory, in other words, the health insurance fund supports the rapid growth of new drugs from foreign companies.
and the major changes to the national health-care directory in 2017 and 2019 provide a valuable opportunity for new drugs from foreign companies to enter the national health-care catalog.
many foreign products to take advantage of the national health insurance catalog, what's more, a pharmaceutical company once into the health insurance catalog varieties are double digits.
with the help of health insurance dividends, increase profits while expanding the market area 01 foreign enterprises high-speed growth era 2009-2019 foreign enterprises in China experienced high-speed growth era, some enterprises in China sales contribution of more than 20%.
example of this is Bayer's Bairetto, which available at an average patient cost of 100 yuan per day, when similar products cost a few dollars a day.
but baitto entered the 2009 National Health Insurance Directory six months after its listing, changing the market landscape, with its competitors entering years later.
, if the product can change the market, help enterprises achieve high growth.
02 The importance of government affairs of foreign enterprises and their business strategy (1) Government affairs is well known, the government affairs department of foreign enterprises belongs to the department directly under the CEO, and even some government affairs departments are led by the CEO part-time, and ranking is second only to the sales department, which shows the contribution of government affairs to enterprises.
(2) The transformation of government affairs from function to business unit With the deepening of China's medical reform, the value of government affairs is highlighted, most corporate government affairs continue to expand, the name is also changed to the Ministry of Market Access, as the name implies, related to market access, from the name can also be seen from the functional departments to business units.
(3) health insurance rapid access strategy is an important strategic foreign enterprises to market new products symbolize another high-speed growth opportunities, especially the arrival of a heavy bomb.
And the excellent listing of new products is also known, in the new product 36 months before the market has begun to prepare for the relevant work, market access in health insurance access is particularly important, corporate health insurance access is a top priority year after year, such as Roche last year after access to a number of products, this year's access target is still not in the minority, its access strength and capacity is far stronger than domestic pharmaceutical companies.
From the 2019 health insurance catalog regular access can be seen, foreign enterprises access more than half, especially some Chinese pharmaceutical companies access capacity is amazing, in more than a year, 2019 a new round of national health insurance catalog adjustment, Novardo a total of 11 products successfully entered the national health insurance catalog, Novardo has thus become a new round of national health insurance catalog adjustment of one of the largest foreign pharmaceutical companies.
2019 edition of the health insurance catalog of Chinese and foreign enterprises, in addition to the use of health insurance access dividends, Novarma Pharmaceuticals is also sinking the market to enhance the access to innovative drugs, and the grass-roots market has become the most dynamic growth of multinational pharmaceutical companies in the region.
IQVIA sample hospital data show that the growth rate of multinational pharmaceutical companies in second-tier, third- and fourth-tier cities in 2018 was as high as 10.9%, 11.9% and 8.8%, respectively;
the relatively weak strength of Otsuka Pharmaceuticals in the last round of medical insurance review also access to three drugs, its strength makes the vast number of domestic pharmaceutical companies eager to be out of reach.
with the help of health insurance dividends, rapid growth, not only in the core cities to occupy a share, began to use health care access to target the grass-roots market.
The introduction of the new policy in 2020, the advantages of access to medical insurance for foreign enterprises or the change of 2020 should be China's first year of medical insurance, the State Health Insurance Administration Order No. 1 issued, "Interim Measures for the Administration of Basic Medical Insurance Drug Use" published, many new rules written into the management methods.
this feat has the potential to change the status quo of China's health insurance foreign enterprises collective, foreign enterprises' access to health insurance advantages with the improvement of the health insurance policy system and end.
The people-centered starting point is an important feature of the new round of medical insurance evaluation 01 clearly defines the basic principles of basic medical insurance drug management to the people-centered principle, concretely embodied in the effective protection of the reasonable drug demand of the insured personnel, reflecting the fundamental purpose of medical insurance drug management.
In fact, foreign enterprises are using the advantages of innovative drugs to meet the needs of the vast number of patients to enter the medical insurance directory, in fact, in addition to rare diseases and a few other drugs, even if foreign companies do not enter the medical insurance directory, will not reduce the level of treatment of Chinese patients, this may also need time to verify.
basic principle of medical insurance reflects the pragmatic attitude of basic medical insurance to do its best and do its best, and the level of drug protection is suitable for the affordability of medical insurance funds and insured persons.
, foreign companies are expensive drugs, especially access to health insurance occupies a large number of health insurance funds, which put pressure on the management of health insurance funds, health operation.
02 The conditions and procedures for the adjustment of the National Drug Catalog have been clarified, the basic conditions for inclusion in the Drug Catalog, the scope of the drug catalogue not included, the conditions for the direct transfer of the Drug Catalog and the conditions for the transfer of the Drug Catalog, and the mechanisms and procedures for the dynamic adjustment of the Drug Catalog have been clarified, on the basis of early exploration and practice. Perfected the expert review, access negotiation, publication results and other catalog adjustment links, and innovatively put forward the enterprise declaration, access bidding and other mechanisms, established in addition to Chinese medicine tablets using expert evaluation methods other drugs using enterprise declaration, expert evaluation, negotiation or access bidding, publication of the results of the adjustment procedures, and the negotiation of renewal made a more clear provision.
One of the innovation points of medical insurance access: enterprise declaration, to provide all pharmaceutical enterprises with fair choice of opportunities, in the past from foreign enterprises more evidence-based evidence of drugs, foreign pharmaceutical companies have greater access opportunities, now "national" pharmaceutical enterprises to participate, domestic pharmaceutical enterprises and foreign enterprises together to run the line of competition, invisible foreign enterprises are increased competitive pressure.
two innovation points of medical insurance access: access bidding, non-exclusive drugs or over-patented drugs are required to bid, which provides equal opportunities for domestic enterprises to generic drugs and patented foreign enterprises to compete for original research drugs.
And negotiating access is well worth promoting, especially by pushing the price of innovative drugs from foreign companies to the lowest in the world, the health-care directory access management provides a good exploration, "Dagle Net" global lowest price is worth further reference.
Innovating drug access for foreign enterprises will welcome domestic innovative drugs to stir up foreign-funded enterprises have been accepting the dividends brought about by the health insurance policy, with the rise of domestic innovative pharmaceutical enterprises, foreign-funded enterprises will continue the dividend period as always? When does the "carnival" end? It is estimated that the period is not far away.
There are several main factors to consider: 01 domestic pharmaceutical enterprises have been approved innovative drugs at present, domestic innovative pharmaceutical enterprises springing up, domestic innovative drugs approval is also accelerating, in the medical insurance assessment, the advantages of domestic innovative drugs are no less than foreign enterprises.
the first PD-1 to enter the national health insurance directory is a domestic innovative drug, Thysin Dilli single resistance, a strong confirmation of the rise of domestic innovative drugs.
02 the voice of domestic pharmaceutical enterprises has gradually been paid attention to the monopoly of foreign enterprises in the academic field for many years, academic communication orientation and voice is also biased towards foreign enterprises.
with the gene of multinational enterprises, global vision and experience, the voice of foreign pharmaceutical companies is more recognized.
The 2020 draft for consultation on health insurance adjustment proposed that the deadline for new drug additions should be December 31, 2019; In the medical insurance adjustment policy, the deadline for new drugs will be relaxed from the end of last year to August 17, 2020, before the release of this year's catalogue adjustment program, and for those innovative drugs that have just been approved, especially those with independent intellectual property rights, to give faster access, domestic pharmaceutical companies through trade associations to the policy authorities to recommend and obtain approval, the time adjustment for the day before the submission of the evaluation materials.
, domestic pharmaceutical companies began to gradually realize the importance of communication, through the right way to recommend, and the policy authorities also pay attention to the needs of domestic pharmaceutical enterprises.
china Pharmaceutical Innovation Promotion Association, said, "This reflects that health care has truly achieved 'patient-centered'."
Pharma innovation is designed to meet the drug needs of patients, and the inclusion of innovative drugs in health insurance as soon as possible not only improves the access of patients' medicines, but also enables pharmaceutical innovators to re-enter the market in a shorter period of time, further encouraging innovation in the pharmaceutical industry."
" adjustment of the access time limit further highlights the encouragement of innovation by the Medical Insurance Bureau, which will help to improve China's medical insurance payment policy and improve China's pharmaceutical innovation ecological environment.
.